On February 18, 2021 Ashvattha Therapeutics, a clinical-stage biotech company focused on the development of novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in oncology, ocular and inflammatory diseases, reported that Jeffrey Cleland, Ph.D., Chairman, CEO & President, is scheduled to attend and present corporate updates at the following investor conferences (Press release, Ashvattha Therapeutics, FEB 18, 2021, View Source [SID1234575295]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

10th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 23 – Private Company Exhibition 1×1 Meetings
H.C. Wainwright Global Life Sciences Conference on Friday, March 5 at 4:00 PM ET. Prerecorded presentation available starting on Tuesday, March 9 at 7:30 a.m. ET (4:30 a.m. PT)
"We are excited to present at these upcoming conferences and give investors an update on our pipeline. We have made extensive progress on our lead program, OP-101, with Phase 2 in severe COVID-19 patients completing enrollment. Our second program, D-4517, for subcutaneous treatment of wet AMD is progressing through IND enabling studies, and demonstration of imaging for brain tumors and brain metastases along with a robust preclinical oncology pipeline," said Jeffrey Cleland, Ph.D., Chairman, CEO & President, Ashvattha Therapeutics.

The webcasts will be accessible in the News section of the Ashvattha Therapeutics website at View Source